Although the aetiology of Crohn's disease (CD) is unknown, there is evidence that alterations in immunoregulation and immune effector mechanisms may be involved in disease pathogenesis.' Studies of T and B cell function in CD have not resulted in the description of a well characterised abnormality. Circulating B cells from CD patients have been shown to spontaneously secrete more immunoglobulins compared with controls."" Circulating and gut derived lymphocyte populations have an increased proliferation when exposed to B cell mitogens, such as lipopolysaccharides (LPS). ' immune responses can also be decreased."'" The data on humoral immune responses to various stimuli in patients with CD are therefore conflicting.
In the present study we took advantage of the fact that healthy individuals usually have high titres of circulating, complement fixing antibodies against purified LPS preparations from various Escherichia coli serotypes. To see if CD patients have an altered response to these enteral bacterial antigens, we determined complement fixing circulating anti-LPS antibodies and antilipid A antibodies in a follow up period during and after flareup of the disease and compared anti-LPS antibody titres with the presence of IgG antitetanus toxoid antibodies. Three different serotypes of E coli were investigated because of their significance in human disease: serotype 014 possesses the so-called enterobacterial common antigen of Kunin which has crossreactivity with human colonic epithelial cells,"'7 serotypes 075 and 0119 are common in the human faecal flora and frequently involved in urinary tract infections.
Methods

PATI ENTS
The study was carried out in 27 patients with Crohn's disease. The diagnosis was established by endoscopical, radiological and histological criteria. Eleven men and 16 women were investigated; age ranged between 15 and 56 years (median 32 years). The study included eight patients with colonic disease, six with small bowel disease and 13 with both colon and small bowel involvement. The disease activity was evaluated by the Crohn's disease activity index (CDAI).'" Twelve patients were followed up over a period of six months during and after treatment for active disease. Patients (CDAI>200) were treated with 6-methyl-prednisolone at a decreasing dose starting with 48 mg and sulphasalazine 3 g/day (n=8) or with continuous intraduodenal infusion of a peptide diet (Peptisorb, Pfrimmer, FRG) through a filiform tube with a peristaltic pump without any drug treatment (n=4). The other 15 patients were on a maintenance dose of prednisolone (dose ranging between 10 and 20 mg per day) (n=8) and/or sulphasalazine (3 g per day) (n=5), seven patients had no drug treatment at the time of the study and two patients received azathioprine 2 mg/kg bodyweight. Twenty age and sex matched normal subjects, including blood bank donors and laboratory personnel, were used as controls. PREPARATION Circulating immune complexes in sera of CD patients were determined by the Clq binding assay as described previously."
STATISTICAL ANAL YSIS
Results were expressed ats median, minimum, and maximum and the Krukal-Wallis non-parametric analysis of variance was done to compare more than two different groups for significant differences. Complement fixing antibodies against highly purified LPS from three different E coli strains as detected in a passive haemolytic assay could be shown in the sera from all healthy individuals (Table 1) . The frequency and distribution of the serum titres in the control group was comparable for the different E coli serotypes (one representative example is shown in Figure 1 ). cases patients in these two antibody groups remained in these groups upon repeat study. In six of 27 CD patients studied, however, rapidly changing titres were noted as indicated in the representative patient antibody profile shown in Figure 2 . The antibody titre changes in this patient subgroup could not be related to disease activity.
In the antibody positive group, three patients were treated with 6-methyl-prednisolone, three with 6-methyl-prednisolone and sulphasalazine, one patient received azathioprine in addition to prednisolone and sulphasalazine, and five were without treatment. In the antibody negative group, four patients were treated with 6-methyl-prednisolone, one with 6-methyl-prednisolone and sulphasalazine, one only with sulphasalazine, two patients were on a residue free oligopeptide diet alone and two had no treatment. Three of six patients with rapidly changing antibody titres were treated with 6-methylprednisolone and sulphasalazine, one on azathioprine alone, one treated with an elemental diet alone and one without treatment. Thus, the form of treatment had no influence on the anti-LPS antibody titres.
In Table 2 , the influence of disease location within the bowel, the presence of extraintestinal manifestations and the presence of fistula on anti-LPS antibody titres is shown. Of the patients with colon involvement one had normal titres of anti-LPS antibodies, three had no detectable antibody titres and four had 
ANTIBODIES AGAINST TETANUS TOXOII)
To investigate if the absence of LPS-specific antibodies is restricted to these antigens, we determined TT-specific IgG in the serum in our patients (Fig. 3) . In the total group, 14 of 24 patients (58%) had clearly detectable amounts of TV-specific IgG (median 25 3 itg/ml, range 2-56-2 Rg/ml) and 10 had no detectable amounts of anti-TV IgG. In the group with anti-LPS antibodies (group 1 in Fig. 3 Fig. 2 ).
Discussion
In the present study we have investigated the presence of complement fixing antibodies against purified LPS preparations from three different E coli strains and against free lipid A, the strain non-specific component of bacterial lipopolysaccharides, in patients with CD and in healthy individuals. The major findings of this study are that (a) certain subgroups of CD patients have an altered response pattern of anti-LPS antibodies in comparison with healthy individuals and (b) that these alterations are not paralleled by changes in specific antibodies to another common antigen (IT), in total immunoglobulin concentrations or by the presence of circulating immune complexes. There is general agreement in most previous studies that patients with inflammatory bowel disease have an increased prevalence and increased titres against faecal microbial antigens.=" This finding is attributed to an increased absorption of bacterial antigens through the intestinal epithelium damaged by the chronic inflammation. Our own finding of decreased or absent complement fixing anti-LPS antibodies in patients with CD therefore seems to be at variance with these previous studies. One possible explanation is that different antibody assays were used. In most previous studies either agglutinating serum antibodies using bacterial suspensions or haemagglutinating antibodies were determined, whereas in our study complement fixing haemolytic antibodies were measured. Another possible explanation is that different antigenic preparations were used. In our study we used purified LPS preparations from three different E coli strains. 
